An international prognostic index to predict the early chemoimmunotherapy failure of diffuse large B-cell lymphoma
{{output}}
Approximately 30-40% of diffuse large B-cell lymphoma (DLBCL) patients will develop relapse/refractory disease, who may benefit from novel therapies, such as CAR-T cell therapy. Thus, accurate identification of individuals at high risk of early chemoimmunothe... ...
